Leading #antibody developer and manufacturer, with over 14,000 primary antibodies and more than 300,000 derived products to accelerate research and discovery.
Presenting antibody-related research at a 2026 conference? Bioss is launching our 2026 Travel Grants to help get your research there!
Submit your abstract here for a chance to win:
https://t.co/xaTeM7AIdB
Which conference is at the top of your list for 2026?
Working on Nipah virus studies? See our latest blog and explore Nipah virus-related recombinant proteins now available from Bioss.
View here: https://t.co/WcMCIY0WTZ
If you’re choosing between antibodies, citation history is often the fastest way to estimate:
🔬 success probability
📉 experimental risk
🧪 reviewer confidence
Read the full breakdown in our new blog 👇
https://t.co/xpZJKzTM6J
In the landscape of biomedical research, few methodologies have reshaped our comprehension of disease pathogenesis as fundamentally as immunohistochemistry; this technique has become a cornerstone of diagnostic and investigative pathology.
Read here: https://t.co/wC0NdbT2xv
This month’s IHC spotlight features bsm-60737R (CD11b), bsm-54767R (CD44), bsm-54132R (AIF1), and bsm-52455R (Ki-67)— critical markers for tracking immune activation, inflammation, microglial response, and cell proliferation.
Visit https://t.co/dcNCbnsZ5q to learn more.
Whether you’re optimizing assays or refining your staining protocols, HRP polymer detection offers the precision and sensitivity needed to elevate your IHC results.
Explore how it works and why it’s redefining immunohistochemistry: https://t.co/UbsK1gpTfv.
We're here to help you stretch your grant funding further with our Best Price offer! Take the most of your research budget now and submit a comparable lower-priced item to us for a discount to apply on your order!
🔗 https://t.co/RuB1HO2v7r
AI is transforming in vitro diagnostics (IVD) by accelerating the discovery and optimization of antibody pairs for ELISA, lateral flow assays, and multiplex platforms.
Read here: https://t.co/7Aj6K1iiHw
A new study in Alzheimer’s & Dementia shows that drugs already used for Parkinson’s disease may improve memory and cognition in Alzheimer’s patients. Could targeting dopamine be the next breakthrough for Alzheimer’s?
Learn more here: https://t.co/YkUdsm9tTm
Recombinant Proteins, Refined for Your Research 🧬
With 9,000+ recombinant proteins available, Bioss supports early discovery to large-scale workflows— without compromising performance.
Explore the collection: https://t.co/Lx39J9DteB
Bioss Knockdown-Validated Recombinant Antibodies are paired with matched lysates for enhanced reliability and better signal specificity.
Explore our portfolio designed to boost confidence in your results here: https://t.co/X94glihpdb
Whether you're outfitting a core lab or running a single project, every dollar counts. We're here to help you stretch your grant funding further— but this limited-time offer won't be around much longer... make the most of your research budget now!
🔗 https://t.co/dzIcmlnXxe
Antibodies power modern research—but not all antibodies are created equal. Batch-to-batch variability can make or break results, which is why researchers are increasingly asking: Should I use recombinant monoclonal antibodies or polyclonals?
🔗 Read here: https://t.co/xwGJ1mE3YI
Bioss Knockdown-Validated Recombinant Antibodies are paired with matched lysates for enhanced reliability and better signal specificity.
Explore our portfolio designed to boost confidence in your results here: https://t.co/HCanJtx0ke